Table 5.
Impact of GP88 and other clinical risk factors on diease-free survival.
| Covariate | Univariate | GP88 adjusted for covariate | |||||
|---|---|---|---|---|---|---|---|
| HR | CI | P-value | P-value | HR | CI | Interaction P-value | |
| GP88 (3+ vs. < 3+) | 5.93 | 3.23 to 10.7 | < 0.0001 | < 0.0001 | 5.93 | 3.29 to 10.68 | - |
| Ethnicity (Caucasian vs. non-Caucasian) | 2.32 | 1.17 to 4.58 | 0.0251 | < 0.0001 | 5.90 | 3.26 to 10.67 | 0.09 |
| Tumor size (> 2 cm vs. ≤ 2 cm) | 1.85 | 1.23 to 2.78 | 0.0052 | < 0.0001 | 5.41 | 2.97 to 9.87 | 0.03 |
| Tumor size (> 5 cm vs. ≤ 5 cm) | 3.09 | 1.37 to 6.96 | 0.0167 | ||||
| Grade (> 1 vs. ≤ 1) | 1.68 | 0.23 to 12.2 | 0.5757 | < 0.0001 | 5.86 | 3.18 to 10.78 | 0.25 |
| Grade (> 2 vs. ≤ 2) | 1.36 | 0.74 to 2.51 | 0.3124 | ||||
| Stage (> 1 vs. ≤ 1) | 2.56 | 1.14 to 5.75 | 0.0116 | < 0.0001 | 4.85 | 2.66 to 8.87 | 0.89 |
| Stage (> 2 vs. ≤ 2) | 4.67 | 2.48 to 8.77 | < 0.0001 | ||||
| Nodal status (Pos. vs. Neg.) | 2.12 | 1.11 to 4.05 | 0.0177 | < 0.0001 | 5.60 | 3.09 to 10.14 | 0.40 |
| Age (> 50 yrs vs. ≤ 50 yrs) | 0.73 | 0.40 to 1.34 | 0.3179 | < 0.0001 | 5.96 | 3.30 to 10.74 | 0.83 |
| PR (Pos. vs. Neg.) | 1.04 | 0.52 to 2.08 | 0.9029 | < 0.0001 | 6.53 | 3.52 to 12.10 | 0.49 |
| Adjuvant endocrine therapy (Pos. vs. Neg.) | 1.66 | 0.80 to 3.45 | 0.1542 | < 0.0001 | 5.89 | 3.27 to 10.62 | 0.58 |
| Adjuvant chemotherapy (Pos vs. Neg.) | 4.33 | 2.08 to 9.04 | < 0.0001 | < 0.0001 | 4.78 | 2.63 to 8.70 | 0.52 |
| Adjuvant radiotherapy (Pos. vs. Neg.) | 10.20 | 5.54 to 19.1 | < 0.0001 | 0.0002 | 3.29 | 1.75 to 6.19 | 0.09 |
CPH analysis was used to examine the impact of GP88 score and other individual clinical risk factors on DFS.
CI, 95% confidence interval; HR, hazard ratio; PR, progesterone receptor. In adjusted analysis, the successive columns provide the HR of elevated GP88 adjusted for each indicator with its P-value and 95% CI and the P-value of the analysis of deviance test statistics for interaction between GP88 and that indicator.